Indeed, CTSS has been proposed as a biomarker and therapeutic target in diverse pulmonary diseases (45), and preclinical studies in cystic fibrosis and COPD models show that CTSS inhibition alleviates mucus hypersecretion, inflammation, and functional decline (46, –, 48). This evidence concerns the gene CTSS and cystic fibrosis.